Johnson & Johnson gears up for 60,000-person COVID-19 vaccine trial, the industry's biggest yet by Eric Sagonowsky fiercepharma.com - With several COVID-19 vaccines already in phase 3 trials and investigators aiming to enroll tens of thousands of participants, Johnson & Johnson is prepping the largest study yet. The drugmaker is planning to enroll a whopping
Author: Editor
VOLUME 4 ISSUE 8: Doug Geinzer, Founder and President, High Performance Providers Discusses Measuring Quality and Saving Plans 40-60% of Health Spend.
Dear Colleagues, Medical Travel Today is excited to bring you an interview with Doug Geinzer, Founder and President, High Performance Providers, a company working closely with self-funded health plans, third-party administrators (TPAs) that represent the plans, their consultants and the high-performance networks they seek out. In this interview, Geinzer discusses his
Spotlight Interview: Doug Geinzer, Founder and President, High Performance Providers
About Doug Geinzer Doug is the founder/president of High Performance Providers, a boutique consulting firm that works with world-class surgeons looking to contract with self-funded health plans. He only represents surgeons that deliver better health outcome for a lower/bundled price. While CEO of Las Vegas HEALS (Healthcare | Education | Advocacy
Industry News: VOLUME 4 ISSUE 8
Telehealth leader Teladoc to buy Livongo in $18.5B deal by Heather Landi Fiercehealthcare.com - Telehealth giant Teladoc is acquiring virtual care company Livongo in a deal valued at $18.5 billion. The deal would combine one of the leaders in the telehealth market with a growing digital health firm that targets chronic disease management. To
Volume 10, Issue 24: Bruce Flunker, President, EBSO Discusses Medical Travel, Specialty Pharma and Telehealth
Dear Colleagues,Medical Travel Today is excited to bring you an interview with Bruce Flunker, President, EBSO, a company under 90 Degree Benefits that designs health plans and administers benefits that meet each employer’s unique needs. In this interview, Flunker discusses innovation in the marketplace, receptiveness to medical travel and the
Spotlight Interview: Bruce Flunker, President, EBSO
About Bruce Flunker Bruce Flunker is president of EBSO, Inc., now a 90 Degree Benefits Company in Milwaukee, Wisconsin, and St. Paul, Minnesota. EBSO, Inc. serves clients throughout the United States with employees in Arizona, Ohio, Illinois and Kentucky. Flunker began his insurance career in 1980, when he joined Wausau Insurance as
Industry News: Volume 10, Issue 24
Even Asymptomatic People Carry the Coronavirus in High Amounts By Apoorva Mandavilli Nytimes.com - Of all the coronavirus’s qualities, perhaps the most surprising has been that seemingly healthy people can spread it to others. This trait has made the virus difficult to contain, and continues to challenge efforts to identify and isolate infected people. To view the
VOLUME 4 ISSUE 7: Kevin Cast, Partner, Archbow Consulting, Discusses Specialty Pharmacy and Personalized Medicine
Dear Colleagues, In this issue, I had the chance to speak with Kevin Cast, Partner, Archbow Consulting, a company helping pharma and biotech companies design, build, and optimize product distribution and patient access strategies. In this interview, Cast explains specialty pharmacy in the era of COVID-19 and how companies can best
Spotlight Interview: Kevin Cast, Partner, Archbow Consulting
About Kevin Cast Kevin Cast's career in the pharmaceutical and biotech industry includes experience in pharma companies, PBMs, service providers, and specialty pharmacies over three decades. Today, as a founding partner of Archbow Consulting, Kevin develops unique strategies to maximize the current supply/service chain, while considering trends that predict future needs.
Industry News: VOLUME 4 ISSUE 7
NeuroOne Medical Technologies Corporation Enters into Exclusive Development and Distribution Agreement for Commercialization of Diagnostic EVO Cortical Electrode Eden Prairie, MN– July 22, 2020– NeuroOne Medical Technologies Corporation (OTCQB: NMTC), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces the execution